Surgery Partners (SGRY)
(Delayed Data from NSDQ)
$22.03 USD
+0.24 (1.10%)
Updated Sep 18, 2025 04:00 PM ET
After-Market: $22.03 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth B Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SGRY 22.03 +0.24(1.10%)
Will SGRY be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SGRY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SGRY
Surgery Partners (SGRY) Q2 Earnings and Revenues Beat Estimates
Danaher (DHR) Q2 Earnings and Revenues Top Estimates
SGRY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Surgery Partners (SGRY) Q1 Earnings and Revenues Miss Estimates
Co-Diagnostics, Inc. (CODX) Reports Q1 Loss, Misses Revenue Estimates
Alignment Healthcare (ALHC) Reports Q1 Loss, Tops Revenue Estimates
Other News for SGRY
Aveanna upgraded at J.P. Morgan on risk-reward setup
SGRY rises 1.07% on September 17, leaving the technical picture intact
SGRY: JP Morgan Initiates Coverage with 'Neutral' Rating | SGRY Stock News
Surgery Partners assumed with a Neutral at JPMorgan
Surgery Partners assumed with a Neutral at JPMorgan